2018
Alcohol withdrawal hallucinations in the general population, an epidemiological study
Stephane M, Arnaout B, Yoon G. Alcohol withdrawal hallucinations in the general population, an epidemiological study. Psychiatry Research 2018, 262: 129-134. PMID: 29433107, DOI: 10.1016/j.psychres.2018.02.021.Peer-Reviewed Original ResearchConceptsOdds ratioBrain developmentHigher odds ratioLogistic regression analysisMost psychiatric illnessesNational Epidemiologic SurveyAlcohol withdrawalClinical patternWithdrawal seizuresPsychiatric comorbidityMechanisms of hallucinationsPsychiatric illnessUnmarried subjectsEpidemiological studiesGeneral populationEpidemiologic SurveyRelated conditionsAnxiety disordersLow levelsSevere exposureHallucinationsSocial isolationRegression analysisAfrican AmericansSuch history
2017
Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder
Feeley RJ, Arnaout B, Yoon G. Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 729-730. PMID: 29028689, DOI: 10.1097/jcp.0000000000000794.Peer-Reviewed Original Research
2010
Escitalopram versus placebo in the treatment of dysthymic disorder
Hellerstein DJ, Batchelder ST, Hyler S, Arnaout B, Toba C, Benga I, Gangure D. Escitalopram versus placebo in the treatment of dysthymic disorder. International Clinical Psychopharmacology 2010, 25: 143-148. PMID: 21811192, DOI: 10.1097/yic.0b013e328333c35e.Peer-Reviewed Original ResearchConceptsHamilton Depression Rating ScaleDysthymic disorderGlobal assessmentSelective serotonin reuptake inhibitorsClinical Global Impressions-SeveritySuperiority of escitalopramPercentage of respondersPlacebo-treated individualsSerotonin reuptake inhibitorsDepression Rating ScaleStructured Clinical InterviewPercentage of participantsLarger study sampleItem total scoresSocial Adjustment ScaleAcute efficacyEscitalopram doseHDRS-24Active medicationReuptake inhibitorsWeek 12Inclusion criteriaSecondary measuresEscitalopramClinical Interview
2007
Aripiprazole as an adjunctive treatment for refractory unipolar depression
Hellerstein DJ, Batchelder S, Hyler S, Arnaout B, Corpuz V, Coram L, Weiss G. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2007, 32: 744-750. PMID: 18164528, DOI: 10.1016/j.pnpbp.2007.11.024.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsAripiprazoleBrief Psychiatric Rating ScaleDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleDrug EvaluationFemaleHumansMaleMiddle AgedPiperazinesProspective StudiesQuinolonesSocial BehaviorTime FactorsTreatment OutcomeConceptsHDRS-24Adjunctive treatmentSNRI medicationsUnipolar depressionCurrent episodeWeek open label studyTreatment-resistant major depressionCurrent DSM-IV diagnosisEffectiveness of aripiprazoleRefractory unipolar depressionOpen-label studyEffective adjunctive treatmentDSM-IV diagnosisFluoxetine equivalentsSNRI treatmentWeek 12Baseline severityMean doseMajor depressionTreatment respondersSide effectsSSRIsMaximum doseAripiprazoleMedications